Market Place
Sourcing Support
Novartis`s Biologic Ilaris Receives Suppl Approval in US
01 Nov 2024 //
FDA
Novartis’ Canakinumab Flunks Another Phase III NSCLC Trial
16 Aug 2022 //
BIOSPACE
Novartis looks for silver lining after 2nd Ilaris NSCLC flop
26 Oct 2021 //
FIERCEPHARMA
Strike two for Novartis’ lung cancer antibody canakinumab
26 Oct 2021 //
PHARMAPHORUM
Novartis hits another setback in plan to repurpose rare disease drug
25 Oct 2021 //
BIOPHARMADIVE
Novartis lung cancer drug fails another Phase III trial
25 Oct 2021 //
GLOBENEWSWIRE
Novartis` canakinumab fails to improve survival in lung cancer study
10 Mar 2021 //
REUTERS
Novartis phase III CANOPY-2 study of canakinumab in combo with chemotherapy
09 Mar 2021 //
PHARMABIZ
Novartis’ arthritis therapy shows no efficacy in hospitalised COVID-19 patients
06 Nov 2020 //
PHARMAFILE
Novartis’ CAN-COVID trial of canakinumab in hospitalized patients with COVID-19
06 Nov 2020 //
PHARMABIZ
Novartis Pharms`s Biological Canakinumab Receives Approval In US
22 Sep 2020 //
FDA
Novartis’ Ilaris [canakinumab] unexpectedly slashes need for joint replacements
05 Aug 2020 //
FIERCEBIOTECH
Novartis’ Ilaris cuts rate of joint replacements from arthritis
03 Aug 2020 //
FIERCE BIOTECH
Novartis nabs new FDA approvals for Ilaris and Cosentyx
19 Jun 2020 //
PM LIVE
Novartis` Ilaris first drug approved for Still`s disease
17 Jun 2020 //
PHARMATIMES
FDA Approves First Treatment for Adult Onset Still’s Disease, Rare Disease
16 Jun 2020 //
FDA
Novartis plans COVID-19 testing for Ilaris
28 Apr 2020 //
FIERCE PHARMA
Once again Novartis’ cardio team looks to beat the odds using sketchy data
03 Sep 2019 //
ENDPTS
The top 10 pipeline blowups, setbacks and snafus for H2 2018
16 Feb 2019 //
ENDPTS
Novartis pulls EU filing for canakinumab
18 Dec 2018 //
PHARMA TIMES
Inflazome brings on ex-Novartis executive as CMO after €40M VC round
30 Nov 2018 //
FIERCE BIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.